Placental derived mesenchymal stem cell therapy - Osiris Therapeutics

Drug Profile

Placental derived mesenchymal stem cell therapy - Osiris Therapeutics

Alternative Names: Grafix; Grafix CORE; Grafix cryopreserved placental membrane; Grafix PRIME; Grafix XC; hCVPM - Osiris Therapeutics; Human cryopreserved viable placental membrane - Osiris Therapeutics; Mesenchymal stem cell therapy - Osiris Therapeutics; OTI-15-01; OTI-15-02

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osiris Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Wounds

Most Recent Events

  • 01 Jun 2017 Osiris Therapeutics terminates a phase III trial for Wounds (chronic diabetic foot ulcer) in USA, due to company's desire to allocate more research and development resources to other clinical programs (NCT02571738)
  • 06 Oct 2016 Efficacy data from a phase IV trial in Diabetic foot ulcer released by Osiris Therapeutics
  • 12 Apr 2016 Pharmacodynamics data from a preclinical study was released by Osiris Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top